{"Clinical Trial ID": "NCT02872103", "Intervention": ["INTERVENTION 1:", "F-627", "F-627, 20 mg fixed-dose pre-filled syringe, 2 day dose of each of the 4 chemotherapy cycles.", "INTERVENTION 2:", "- Placebo", "Placebo, pre-filled syringe administered Day 2 of the first chemotherapy cycle; and F-627, 20 mg, fixed-dose pre-filled syringe administered Day 2 of each of the following 3 chemotherapy cycles."], "Eligibility": ["Incorporation criteria:", "Demonstrate a signed and dated informed consent document indicating that the patient has been informed of all relevant aspects of the trial.", "Women 18 years of age and under 75 years of age.", "Diagnosis of breast cancer in stage II-IV.", "The patient should undergo 4 cycles of chemotherapy TA (docetaxel, doxorubicin, 75 and 60 mg/m2, respectively).", "ECOG Performance status of 2.", "Number of white blood cells (WBC) 4.0 109/L, hemoglobin 11.5 g/dL and platelet count 150 109/L.", "Demonstrate adequate renal and hepatic function (Livernal function tests (ALT, AST, alkaline phosphatase and total bilirubin) should be less than 2.5 times the upper limits of normal (LSN). Serum creatinine should be less than 1.7 times the ULN.", "All subjects should agree to use at least one of the following types of contraception: intrauterine device, implantable progesterone device, intramuscular injection of progesterone, or oral contraceptive, which has been started at least one month prior to the visit and will continue throughout the trial. Contraceptive device or the use of spermicide condoms is also an acceptable form of contraception as long as they are used continuously throughout the trial.", "- Exclusion criteria:", "The person is < 18 or 75 years of age.", "A progression of the disease occurred during treatment with taxane.", "The subject underwent radiation therapy within 4 weeks of registration.", "The subject underwent bone marrow or stem cell transplantation.", "The subject has a history of previous malignancy other than breast cancer that is NOT in remission.", "Subjects who have used G-CSF or any other drug that may potentiate the release of neutrophils (i.e. lithium) within 6 weeks of the screening period are excluded.", "The subject received chemotherapy within 365 days of screening.", "The subject documented congestive heart failure, cardiomyopathy or myocardial infarction by clinical diagnosis, ECG or any other relevant test.", "History of alcohol or drug abuse that would interfere with the ability to comply with the study procedure.", "The unwillingness to participate in the study.", "Any underlying medical condition that, in the opinion of the investigator, would make the administration of a study drug dangerous to the patient or obscure the interpretation of adverse events.", "By receiving other experimental or biological medicinal products within one month or five half-lives of registration.", "Any condition, which may cause splenomegaly.", "\u2022 Chronic constipation or diarrhoea, irritable intestinal syndrome, inflammatory bowel disease.", "ALT, AST, alkaline phosphatase, total bilirubin 2.5 upper limit of normal.", "\u2022 Subject with active infection, or known to have been infected with chronic active hepatitis B in the past year (unless it has been demonstrated at the time of entry into the study that it was negative for hepatitis B antigen), or with a history of hepatitis C.", "Pregnant or lactating women.", "Subject known to be HIV-positive, or who has had a disease that defines AIDS or a known immunodeficiency disorder.", "Subject with a history of tuberculosis or TB exposure Patients who have received a prior pulmonary X-ray for suspected TB are also excluded unless they have been confirmed negative for PPD or have had a latent tuberculosis previously treated.", "Subjects with sickle cell disease", "Subjects with known hypersensitivity to pegfilgrastim filgrastim proteins derived from E.coli or any other component of the medicinal product studied."], "Results": ["Performance measures:", "The duration of 4th year days (severe) Neutropenia observed in the chemotherapy cycle 1 compared to Placebo", "Approximately 24 hours after chemotherapy, subjects will receive a fixed dose of 20mg F-627 or Placebo. The absolute number of neutrophils (NACs) of the subject will be monitored daily after chemotherapy until the NAC level exceeds 2.0x10^9/L, and then the value will be monitored every three days until the next chemotherapy cycle begins. The duration of Grade 4 neutropenia (NAC <0.5x10^9/L) in this cycle is the primary efficacy criterion.", "Timeline: The first of the 4 21-day chemotherapy cycles, an average of 3 weeks", "Results 1:", "Title of arm/group: F-627", "Description of the arm/group: F-627, 20 mg fixed-dose pre-filled syringe, 2 day dose of each of the 4 chemotherapy cycles.", "Total number of participants analysed: 83", "Average (standard deviation)", "Unit of measurement: days 1.3 (1.17)", "Results 2:", "Title of the arm/group: Placebo", "Description of the arm/group: Placebo pre-filled syringe administered on day 2 of the first chemotherapy cycle; and F-627, 20 mg Fixed-dose pre-filled syringe administered on day 2 of each of the following 3 chemotherapy cycles.", "Total number of participants analysed: 39", "Average (standard deviation)", "Unit of measurement: days 3.9 (1.35)"], "Adverse Events": ["Undesirable Events 1:", "Total: 4/83 (4.82%)", "*3/83 (3.61 per cent)", "Diarrhoea *0/83 (0.00 %)", "Pneumonia *0/83 (0.00 %)", "Tumour haemorrhage *1/83 (1.20%)", "Adverse Events 2:", "Total: 10/39 (25.64%)", "*10/39 (25.64%)", "Diarrhoea *1/39 (2.56%)", "Pneumonia *0/39 (0.00 %)", "Tumor haemorrhage *0/39 (0.00 %)"]}